-
DHEA as a Stress-Response Research Tool
2026-09-15
Dehydroepiandrosterone (DHEA) is a context-dependent steroid research tool spanning neuroprotection and ovarian biology. This guide connects DHEA assay design with new evidence on oxidative stress, endoplasmic reticulum stress, and granulosa-cell apoptosis while defining critical interpretation limits.
-
PRMT5, Splicing, and Glutamine Vulnerability in Neuroblastom
2026-09-15
The reference study shows that MYCN-amplified neuroblastoma is unusually dependent on PRMT5-regulated RNA splicing, epitranscriptomic control, and glutamine metabolism. By combining transcriptomics, isotope tracing, molecular validation, and a genetically relevant mouse model, the authors connect spliceosomal disruption with reduced GLS protein and metabolic stress.
-
nor-NOHA Acetate: Cancer Assay Workflows
2026-09-14
Build reversible arginase-inhibition experiments around nor-NOHA acetate, from HepG2 apoptosis and invasion assays to endothelial and AML immunometabolic models. This workflow combines solvent discipline, orthogonal readouts, and explicit limits on cross-domain interpretation.
-
AG-120 (Ivosidenib) AML Research Workflows
2026-09-14
Build more informative IDH1-mutant AML assays with AG-120 (Ivosidenib), combining proximal 2-hydroxyglutarate reduction with differentiation and metabolic readouts. The workflow also translates CD44-driven metabolic rewiring into practical resistance and combination-testing experiments.
-
Cefotaxime for AMR Transmission Assays
2026-09-13
Cefotaxime can connect antimicrobial susceptibility phenotypes with plasmid localization, gene transfer, and strain relatedness. This article develops an evidence-calibrated assay framework inspired by a 2025 Enterobacter cloacae transmission study, while defining what Cefotaxime can—and cannot—demonstrate.
-
Covalent SARS-CoV-2 Mpro Binders from HCV Drugs
2026-09-12
The reference study combines crystallography, binding assays, and molecular docking to show that three clinically approved hepatitis C drugs and two additional drug-like compounds covalently engage the SARS-CoV-2 main protease catalytic residue Cys145. Its main contribution is a structural rationale for antiviral drug repurposing, while also showing why biochemical binding evidence must be followed by cellular, pharmacological, and clinical validation.
-
Pyridostatin TFA: G-Quadruplex Research Guide
2026-09-12
Pyridostatin TFA is a synthetic G-quadruplex stabilizer used to study telomere dysfunction, DNA secondary structure, and cancer cell growth. Product information reports preferential in vitro cytotoxicity toward HT1080 fibrosarcoma cells versus WI-38 fibroblasts, while recent research shows that RNA G-quadruplexes can also modulate TDP-43 condensation and toxicity.
-
Angiotensin 1/2 (1-6): From RAS to Translation
2026-09-11
Angiotensin 1/2 (1-6) is more than a short renin-angiotensin system fragment. Its defined sequence, vascular relevance, and emerging role in spike–AXL binding make it a useful probe for connecting cardiovascular, renal, and viral pathway research while preserving the discipline required for translational interpretation.
-
A-1210477 Workflow for MCL-1 Apoptosis
2026-09-11
A-1210477 is a selective MCL-1 inhibitor for distinguishing MCL-1-dependent survival from nonspecific cytotoxicity in cancer models. This practical workflow combines mitochondrial readouts, dependency controls, and navitoclax combination testing while clearly separating useful in vitro evidence from in vivo translation limits.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-10
The reference study develops chemically modified CDKN1A/p21 mRNA packaged in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its preclinical evidence links bladder-localized p21 restoration with cell-cycle suppression, DNA damage, apoptosis, and reduced orthotopic tumor growth, while also identifying important translational limitations.
-
Angiotensin 1/2 (1-6): A Smarter Assay Framework
2026-09-10
Angiotensin 1/2 (1-6), an Asp-Arg-Val-Tyr-Ile-His hexapeptide, offers a defined tool for separating peptide-length effects from receptor-specific biology. This evidence-led guide explains how to design cardiovascular, renal, and exploratory spike–receptor binding assays without overinterpreting mechanistic findings.
-
Indomethacin: Practical Protocol and QC Guide
2026-09-09
This dossier-led guide explains how to prepare, control, and interpret Indomethacin in COX inhibition, inflammation research, lipid metabolism study, and membrane signaling workflows. It is intended for controlled laboratory experiments, not as a substitute for model-specific validation, clinical dosing, or assumptions that product IC50 values transfer directly to cell-based systems.
-
Early Life Adversity, Oxytocin, and Innate Defense
2026-09-09
A 2026 Communications Biology study reports that social deprivation during a defined postnatal period weakens looming-evoked innate defensive behavior in mice through disrupted oxytocin signaling in the superior colliculus. The work links developmental adversity to a specific hypothalamus–midbrain circuit and shows that intranasal oxytocin can ameliorate the behavioral deficit, while also identifying important boundaries for translation.
-
Trelagliptin, RUNX2, and Osteoblast Differentiation
2026-09-08
The reference study identifies a previously underexplored effect of the DPP-4 inhibitor trelagliptin: enhancement of osteoblastic differentiation and mineralization in MC3T3-E1 cells. Its data connect trelagliptin with increased RUNX2 and AMPK activation, providing a mechanistic basis for osteoporosis research while remaining preliminary because the evidence is limited to an in vitro cell model.
-
MLN4924 HCl Salt: Neddylation to Viral Immunity
2026-09-08
A translational perspective on how MLN4924 HCl salt connects NAE-dependent cullin-RING ligase control with cancer biology, necroptosis, and virus-induced inflammation.